Abbott Laboratories reported Q4 revenue of approximately $11.5 billion, marking a 4.4% year-over-year increase driven by robust double-digit growth in its Medical Devices segment. Continuous glucose monitoring (CGM) systems led the charge with growth exceeding 12%, offsetting an 8–9% decline in the Nutrition segment and headwinds in COVID-19 diagnostics. Adjusted EPS of $1.50 matched consensus estimates, while gross margins expanded by 150 basis points, reflecting cost efficiencies and product mix improvements.

Management reaffirmed its medium-term targets, guiding for 7% sales growth and 10% EPS growth in fiscal 2025, underpinned by ongoing innovation in diabetes care and normalization in Nutrition. For full year 2026, Abbott projects EPS between $5.55 and $5.80, alongside 6.5%–7.5% revenue growth. These forecasts assume continued margin expansion from productivity initiatives and mid-single-digit growth in Established Pharmaceuticals, partially offset by lingering pressures in diagnostics.

The January pullback, driven largely by market anxiety over segment rotation rather than fundamental deterioration, has pushed the stock back into what many commentators consider an attractive entry range. Analysts highlight Abbott’s 7% dividend increase, strong free cash flow generation of over $7 billion in the trailing twelve months, and $5 billion share repurchase authorization as catalysts for long-term total return. Put option activity spiked in late January, but most strategists view the move as a knee-jerk reaction.

Twenty-two brokerages covering Abbott maintain an average recommendation of Moderate Buy, with seventeen Buy and two Strong Buy ratings. Price targets, recently adjusted lower to reflect near-term Nutrition softness, still imply upside potential of 10%–15%. Abbott’s dividend was raised by 7% to an annualized $2.52 per share, representing a payout ratio near 68% and a yield above 2.3%. The company has increased its dividend for 50 consecutive years, reinforcing its Dividend King status.